CJA JCA include a slow onset, long-duration oral CB1 receptor agonist, nabilone, an anti-hypertensive, lofexidine in combination with the oral cannabinoid, dronabinol, an opioid antagonist, naltrexone, and the GABAergic agonist, gabapentin.
Introduction: To report on highlights of a longitudinal study of gamblers, the Alberta Leisure, Lifestyle, Lifecycle Project (LLLP) as well as comparisons with the Ontario Quinte Study.
Method: Five LLL cohorts of gamblers (ages 13-15, 18-20, 23-25, 43-45, and 63-65) have been recruited through Random Digit Dialing (RDD) since February 2006. The cohorts are stratified by large and small urban centers and over-sampled for at-risk gamblers. Four data collections have occurred with initial telephone and face-toface interviews, followed by web-based surveys. The selection of survey instruments reflected a biopsychosocial model of gambling. Introduction: In the general population, problemgambling severity lies across a spectrum, ranging from non-gambling through recreational gambling to problematic gambling. Cross-sectional data indicate that subsyndromal levels of gambling (i.e., not meeting the threshold for pathological gambling or in DSM-5 gambling disorder) are associated to varying degrees with poor health, particularly psychopathology. However, few studies have investigated incident psychiatric or general medical conditions with respect to problem-gambling severity.
Results
Methods: Secondary analysis of data from waves 1 and 2 of the National Epidemiological Survey of Alcohol and Related Conditions was conducted. The 2 waves (collected from 2001-2002 and 2004-2005, respectively) included at wave 1 measures of problem-gambling severity (operationalized using inclusionary criteria for pathological gambling with individuals acknowledging one or more criteria categorized as having at-risk/problematic gambling -ARPG) and at waves 1 and 2 measures of psychiatric and medical conditions. Logistic regression analyses were conducted to examine the extent to which ARPG prospectively related to new (incident) psychiatric and general medical conditions.
Results: Relative to non-ARPG, ARPG was prospectively associated with: 1) incident nicotine dependence among adult women; 2) incident alcohol use disorders among adult men; 3) incident anxiety disorders and substance use disorders among older adults; and 4) incident cardiovascular conditions among older adults.
Conclusions: The findings of incident psychiatric disorders and cardiovascular conditions in relation to ARPG suggest that public health policies and initiatives should incorporate considerations relating to problemgambling severity.
A PHARMACOGENETIC STUDY OF NALTREXONE IN KOREAN ALCOHOLICS
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Introduction: According to a recent pharmacogenetic study, patients with alcohol dependence (AD) who have one or two 118G alleles (G carriers) respond better to naltrexone than those who have the A/A genotype of the A118G mu opioid receptor (G non-carriers). This study was conducted to prospectively investigate the relationship between genotype and response to open label naltrexone treatment in Korean subjects with AD.
Methods: Sixty-three subjects with AD were prescribed naltrexone for 12 weeks in combination with cognitive behavioral therapy. Thirty-two subjects were adherent and took the medication on at least 80% of the treatment days (16 G carriers and 16 G non-carriers).
Results: The G carriers adherent to the naltrexone treatment took a significantly longer time than the G noncarriers (p=0.014). The G carriers treated with naltrexone had a 10.6 times greater relapse rate than G non-carriers (p=0.072).
Conclusions: These results demonstrate a higher therapeutic effect of naltrexone in Korean subjects with AD who have one or two 118G alleles compared to those who have the A/A genotype. Considering that Asians are more frequent G carriers for the A118G mu opioid receptor polymorphism than Caucasians, naltrexone might be more effective for treating AD in Asians than Caucasians.
ARE THERE ANY BENEFITS FROM REDUCING ALCOHOL CONSUMPTION?
Hannu Alho
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Alcohol contributes substantially to the global burden of disease and is the fifth leading disorder of DALYs in 2010 (GBD 2010 study) worldwide, and thus is one of the largest avoidable risk factors. Any reduction in dose of alcohol consumed, as well as in frequency of drinking occasions and the amount drunk on a single occasion will have an immediate impact in reducing alcohol-related injuries, the cardiovascular events and mortality related to heavy episodic drinking. Several examples demonstrate that total alcohol consumption has a significant impact on chronic consequences of excessive drinking. However, many treatment programs promote abstinence as the only/main acceptable treatment goal. Thus, many problem drinkers decline treatment programs aimed at abstinence. Offering both abstinence and no abstinence treatment goals to clients, permits a client-centered approach that contributes to alleviate client's resistance to change. The new DSM-5 introduces a diagnostic shift from the binary diagnostic criteria of alcohol dependence and alcohol abuse, to a single continuum of alcohol use disorders introducing a clear measure of severity such that treatment goals can be modified individually.
In conclusion, reduction strategies offer an opportunity to address patient heterogeneity and lower the treatment threshold by bringing new patients into the treatment.
CAN ALCOHOL DEPENDENT PATIENTS REDUCE THEIR ALCOHOL CONSUMPTION?
Karl F. Mann
Central Institute of Mental Health, Mannheim, Germany
Abstinence has been the predominant treatment goal in alcoholism. There is no doubt that this approach has helped very many people around the world to overcome their alcohol problems. On the other hand, the abstinence goal is a very high threshold which may be one reason why we reach only about 10 % of patients in need for treatment.
